On Wednesday, Shares of Sprint Corporation (NYSE:S), gained 2.66% to $5.01.
Android 6.0, known as Marshmallow, is coming to Sprint! HTC One® A9 will be available Nov. 6 as Sprint’s first smartphone to launch with the newest version of the Android operating system.
Through Jan. 7, qualifying customers pay $20 per month for a 24-month lease of HTC One A91 with Sprint Lease. Also, for a limited time, customers activating a new HTC One A9 will receive two monthly service credits of $20 each after activation. This $40 savings is available when activating the device through Sprint Lease at Sprint retail stores, sprint.com or 1-800-Sprint.
“Innovation is at the core of everything we do at Sprint,” said David Owens, senior vice president of Product Development for Sprint. “We are excited to bring HTC One A9 to our customers as our first Android 6.0 device launch. Sprint will even pay two months of your lease payments – it’s a great deal on a great device.”
HTC One A9’s fun and useful features comprise a 13MP rear camera featuring Optical Image Stabilization (OIS) to minimize hand shake and correct vibrations for a crystal-clear picture. The Hyperlapse editing tool lets users speed up videos to 12 times as fast for a dramatic time-lapse effect. Vibrant 24-bit high definition sound quality comes from the combination of a high-output amp integrated into the headset combined with Dolby Audio™ Surround technology. It is also one of the few smartphones available recently with an expandable microSD™ memory slot (card sold separately).
Sprint Corporation, through its auxiliaries, provides various wireless and wireline communications products and services to consumers, businesses, government subscribers, and resellers in the United States, Puerto Rico, and the U.S. Virgin Islands. The company’s Wireless segment offers wireless data communication services, counting mobile productivity applications, such as Internet access, messaging, and email services; wireless photo and video offerings; location-based capabilities comprising asset and fleet administration, dispatch services, and navigation tools; and mobile entertainment applications.
Shares of Boston Scientific Corporation (NYSE:BSX), inclined 9.39% to $18.40, during its last trading session.
Boston Scientific Corporation, generated sales of $1.888 billion during the third quarter ended September 30, 2015, contrast to the company’s guidance range for the quarter of $1.790 to $1.840 billion. This represents 9 percent operational revenue growth (constant currency basis, not taking into account divested businesses) and an improvement of 2 percent on a stated basis, all contrast to the prior year period. The company achieved adjusted earnings per share of $0.24 for the period, contrast to $0.20 a year ago, and stated a GAAP loss of $198 million, or $(0.15) per share, contrast to earnings of $0.03 a year ago.
Third quarter financial results and recent developments:
- Stated third quarter sales of $1.888 billion, representing 9 percent operational revenue growth and an improvement of 2 percent on a stated basis, all contrast to the prior year period.
- Achieved 5 percent organic revenue growth. Organic revenue growth excludes the impact of sales from divested businesses, changes in foreign currency exchange rates and sales from the acquisitions of the interventional business of Bayer AG (Bayer) and the American Medical Systems (AMS) male urology portfolio over the prior year period.
- Delivered adjusted earnings per share of $0.24 contrast to the company’s guidance range of $0.21 to $0.23 per share, and stated a GAAP loss of $(0.15) per share contrast to the company’s guidance range of $0.10 to $0.13 per share, primarily due to litigation-related charges.
- Achieved third quarter revenue growth of 17 percent in MedSurg (8 percent organic), 9 percent in Cardiovascular (6 percent organic) and 2 percent in Rhythm Administration (2 percent organic), all on a constant currency basis over the prior year period.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.